Search

Your search keyword '"Avard, Denise"' showing total 56 results

Search Constraints

Start Over You searched for: Author "Avard, Denise" Remove constraint Author: "Avard, Denise" Database MEDLINE Remove constraint Database: MEDLINE
56 results on '"Avard, Denise"'

Search Results

1. Using Newborn Screening Bloodspots for Research: Public Preferences for Policy Options.

2. Statement of principles on the return of research results and incidental findings in paediatric research: a multi-site consultative process.

3. Expectations and values about expanded newborn screening: a public engagement study.

4. Public concerns regarding the storage and secondary uses of residual newborn bloodspots: an analysis of print media, legal cases, and public engagement activities.

5. To disclose, or not to disclose? Context matters.

6. SOCIO-ETHICAL ISSUES IN PERSONALIZED MEDICINE: A SYSTEMATIC REVIEW OF ENGLISH LANGUAGE HEALTH TECHNOLOGY ASSESSMENTS OF GENE EXPRESSION PROFILING TESTS FOR BREAST CANCER PROGNOSIS.

7. Ethics education for clinician-researchers in genetics: The combined approach.

8. Public views on participating in newborn screening using genome sequencing.

9. Returning incidental findings from genetic research to children: views of parents of children affected by rare diseases.

10. Attitudes of parents toward the return of targeted and incidental genomic research findings in children.

11. FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project.

12. Whole-genome sequencing in newborn screening programs.

13. Defining the Scope of Public Engagement: Examining the "Right Not to Know" in Public Health Genomics.

15. A new twist on an old problem: primary care physicians and results from direct-to-consumer genetic testing.

16. Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk.

17. Cohort profile: the maternal-infant research on environmental chemicals research platform.

18. Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting.

19. Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to consider.

20. Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited.

21. Personalized medicine and access to health care: potential for inequitable access?

22. Emerging issues in paediatric health research consent forms in Canada: working towards best practices.

23. Recruiting terminally ill patients into non-therapeutic oncology studies: views of health professionals.

24. Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation.

25. Beyond dissemination: A knowledge translation model to drive change in pediatric genetics.

26. Paediatric biobanks: what makes them so unique?

27. Citizens' values regarding research with stored samples from newborn screening in Canada.

29. Pediatric research and the return of individual research results.

30. Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms?

33. Regulatory approval for new pharmacogenomic tests: a comparative overview.

34. The communication of pharmacogenetic research results: participants weigh in on their informational needs in a pilot study.

35. Direct-to-consumer genetic testing: driving choice?

36. Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening.

37. Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors.

38. 'Principled' personalized medicine?

40. Factors influencing intrafamilial communication of hereditary breast and ovarian cancer genetic information.

41. Genomic medicine: considerations for health professionals and the public.

43. An ethical and legal overview of pharmacogenomics: perspectives and issues.

44. Guidance for considering ethical, legal, and social issues in health technology assessment: application to genetic screening.

45. Newborn blood spot screening in four countries: stakeholder involvement.

48. Newborn screening by tandem mass spectrometry: ethical and social issues.

49. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.

50. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation.

Catalog

Books, media, physical & digital resources